M5542 / EMD Serono - LARVOL DELTA

M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases (ACR Convergence 2024) - "To explore whether dual pathway blockade is superior to single pathway blockade, we investigated the in vitro potency and in vivo efficacy of M5542, a novel CD80, CD86, and OX40L antagonist, and a bi-functional fusion molecule that blocks the CD28 and OX40 pathways to inhibit T-cell activation and function, thereby curbing inflammation in autoimmune diseases. M5542, single agent comparators abatacept (CTLA4Ig) and anti-OX40L, or the combination thereof were tested for their ability to inhibit proinflammatory cytokine production in a mixed lymphocyte reaction (MLR) of activated monocyte-derived dendritic cells (MDDCs) and T-cells from healthy donors or SLE peripheral blood mononuclear cells (PBMCs). M5542 effectively blocked CD28 and OX40 mediated T-cell activation and reduced T-cell driven inflammation, demonstrating promise in treating autoimmune diseases."

Graft versus Host Disease • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD80 • CD86 • IFNG • IL6 • TNFA • TNFSF4